-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levoxiracetam in Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levoxiracetam in Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levoxiracetam in Cognitive Impairment Drug Details: L-oxiracetam is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levoxiracetam in Memory Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levoxiracetam in Memory Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levoxiracetam in Memory Impairment Drug Details: L-oxiracetam is under development for the...
-
Product Insights
Memory Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Memory Impairment - Drugs In Development, 2023’, provides an overview of the Memory Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Memory Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – levoxiracetam
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry levoxiracetam Drug Details L-oxiracetam is under development for the treatment of memory and cognitive...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Disease – Global Clinical Trials Review, H1 2020
GlobalData's clinical trial report, “Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Global Clinical Trials Review, H1, 2020" provides an overview of Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastrointestinal Bleeding (Gastrointestinal Hemorrhage). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...